Asarina Pharma

About Us

Asarina Pharma Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Our product pipeline is built on over 40 years of research, and with our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions from Tourette syndrome to OCD..

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Asarina Pharma AB (publ) Interim Report Q3 2019 released

Wed, Nov 20, 2019 08:00 CET

Asarina Pharma CEO Peter Nordkild: “During an intense third quarter we achieved some important milestones. We enrolled the last patient in our landmark PMDD study, received FDA approval for our IND in menstrual migraine and included the first patient in our menstrual migraine study. After the end of the quarter a new directed share issue was subscribed to by a small group of distinguished institutional investors, generating net proceeds of SEK 44.5 million.”FINANCIAL HIGHLIGHTS 1 July – 30 September 2019 · Due to increased R&D activities, operating costs grew to SEK 21.8 million ·

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Asarina Pharma AB (publ) Interim Report Q3 2019 released

Subscribe